



COMPANY OVERVIEW

Cerecor is a biopharmaceutical company developing innovative therapies at the cutting edge of science. Our pipeline, filled with forward-thinking ideas, propels us forward. We are driven to change the lives of patients with rare pediatric and orphan diseases.

RECENT NEWS

FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19

May 11 2021, 7:00 AM EDT

Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still's Disease

May 5 2021, 7:00 AM EDT

STOCK OVERVIEW

Symbol	CERC
Exchange	Nasdaq
Market Cap	228.25m
Last Price	\$2.36
52-Week Range	\$1.98 - \$4.50

05/12/2021 04:00 PM EDT

INVESTOR RELATIONS

ir@cerecor.com

MANAGEMENT TEAM

Michael Cola

Chief Executive Officer

Schond L. Greenway

Chief Financial Officer

James A. Harrell, Jr.

Chief Commercial Officer

Dr. Garry Neil, MD

Chief Scientific Officer

Younok Dumortier Shin, PhD, MBA

Chief Technology Officer

Chris Sullivan

Chief Accounting Officer

H. Jeffrey Wilkins, MD

Chief Medical Officer

Lisa Hegg Ph.D.

Vice President Research and Development Programs and Project Management

Colleen Matkowski

Vice President Global Regulatory Affairs

CERECOR, INC.

540 Gaither Road
Suite 400
Rockville, MD 20850

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.